Detail of the clinical trial
| Title of the trial | An open label, randomized (2:1) Phase 2b study of Dasatinib vs. Imatinib in patients with Chronic Phase Chronic Myeloid Leukemia who have not achieved an optimal response to 3 months of therapy with 400 mg Imatinib |
|---|---|
| EudraCT number | 2011-006181-41 |
| Protocol number | CA180399 |
| Sponsor | Bristol-Myers Squibb International Corporation,Chaussée de La Hulpe 185,Brussels,1170 |
| Indications | Oncology |
| Diagnosis | Chronic Myeloid Leukemia |
| Population in clinical trial |
Adults (18-65 years) Elderly ( > 65 years) Male Female Patients |
| Year of receiving the request to Institute (SÚKL) | 2012 |
| Date of approval by Institute (SÚKL) | 17.1.2013 |
| Date of approval by EC | 11.1.2013 |
| Date of initiation CT in ČR | 7.11.2013 |
| Date of ending CT in ČR | |
| Notice | |
| Sites |
Fakultni nemocnice Olomouc,Hematoonkologicka klinika, I.P.Pavlova 6,Olomouc, 775 20 (discontinued) Fakultni nemocnice Kralovske Vinohrady,Interní hematologická klinika,Srobarova 50,Praha 10,100 34 (discontinued) Fakutni nemocnice Brno,Interní hematologická a onkologická klinika,Jihlavska 20,Brno,625 00 (discontinued) Fakultni nemocnice Hradec Kralove,2.interni klinika,odd. klinicke hemalologie ,Sokolska 581,Hradec Kralove,500 05 (discontinued) Ústav hematologie akrevní transfůze, U nemocnice 1,128 00 Praha 2 |
cz